MedTrace Logo

Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

NCT00588146 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-02-22

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the safety and tolerability of pegylated interferon alpha-2b (PEG-Intron) in patients with severe complications related to Hereditary hemorrhagic telangiectasia (HHT).

Funding Source - FDA Office of Orphan Products Development (OOPD)

Conditions

Interventions

DRUG

Pegylated Interferon Alpha2b

Weekly subcutaneous injection of 1 microgram/kg/week

OTHER

Standard care

Standard care

Sponsors & Collaborators

  • Augusta University

    collaborator OTHER

  • Unity Health Toronto

    collaborator OTHER

  • Schering-Plough

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Karen L Swanson, DO · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00588146 on ClinicalTrials.gov